Aerie Pharmaceuticals Inc (AERI) 12.87 $AERI
Nasdaq stocks posting largest volume increases
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.28 (-0.05), SPNC: 26.52 (-8.18), DNBF: 25.62 (+0.62), LPCN: 6.85 (-0.27), GBNK: 15.74 (-1.12), AERI: 12.87 (-22.52), PFBX: 9.33 (+0.12)
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MXWL: 6.33 (-0.85), SPNC: 26.52 (-8.18), AMSC: 6.88 (-3.12), HWAY: 17.61 (-1.89), NTGR: 30.00 (-4.17), AERI: 12.87 (-22.52)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against Aerie Pharmaceuticals, Inc.
Business Wire - Fri Apr 24, 4:05PM CDT
The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) resulting from allegations that Aerie may have issued materially misleading business information to the investing public.
AERI: 12.87 (-22.52)
Investor Alert: Investigation of Aerie Pharmaceuticals, Inc. Announced by Holzer & Holzer, LLC
Business Wire - Fri Apr 24, 12:36PM CDT
Holzer & Holzer, LLC is investigating whether recent statements issued by Aerie Pharmaceuticals, Inc. LTD ("Aerie" or the "Company"
(Nasdaq: AERI) regarding its business and operations complied with federal and state laws. On April 23, 2015, Aerie announced that its experimental drug, Rhopressa, failed to achieve its primary efficacy endpoint during recent Phase 3 registration trials. The price of Aerie stock fell significantly on the news as the company was downgraded by analysts.
AERI: 12.87 (-22.52)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:45AM CDT
INNL: 9.90 (+1.28), AWAY: 27.18 (-4.99), ACTG: 11.10 (+1.08), AERI: 12.87 (-22.52), DV: 30.70 (-6.87), CVTI: 33.15 (-2.44), MXWL: 6.33 (-0.85), TBI: 29.20 (+4.39), NFEC: 2.13 (-0.17), SPNC: 26.52 (-8.18), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), CPRX: 3.69 (-0.98), LOOK: 1.97 (+0.37), TRN: 28.70 (-4.66), IMH: 19.20 (+4.78), PGI: 10.79 (+1.29), FPP: 1.69 (+0.46), LEU: 5.22 (+0.58), EHTH: 13.50 (+2.06)
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc.
PR Newswire - Fri Apr 24, 11:00AM CDT
Bernstein Liebhard LLP is investigating whether (i) Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company" (NASDAQ: AERI) issued materially false and misleading statements to investors in violation of the federal securities laws; or (ii) the Board of Directors of Aerie breached their fiduciary duties to shareholders.
AERI: 12.87 (-22.52)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:17AM CDT
AMZN: 445.10 (+55.11), EMES: 44.65 (-5.95), ANY: 4.08 (-0.19), DDD: 27.23 (-2.92), AERI: 12.87 (-22.52), INFY: 31.81 (-3.15), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), TRIL: 24.21 (+2.05), JNPR: 26.14 (+2.14), AMCN: 4.95 (-0.05), AMSC: 6.88 (-3.12), UEC: 2.31 (-0.09), LOOK: 1.97 (+0.37), CTSO: 7.52 (+0.50), RMD: 65.70 (-7.68), SSYS: 51.28 (-3.29), LPCN: 6.85 (-0.27), HMHC: 24.21 (-0.13), MSFT: 47.87 (+4.53), EHTH: 13.50 (+2.06)
Aerie Pharma plunges aftermarket as Rhopressa study fails
AP - Thu Apr 23, 5:42PM CDT
NEW YORK (AP) — Shares of Aerie Pharmaceuticals lost two-thirds of their value in after-market trading after the company said its experimental eye pressure drug Rhopressa failed in a late-stage clinical trial.
AERI: 12.87 (-22.52)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:39PM CDT
MXIM: 32.78 (-1.96), AMZN: 445.10 (+55.11), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), UBNT: 31.29 (-0.14), AWAY: 27.18 (-4.99), ALGN: 59.18 (+3.17), ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52), RIGL: 4.88 (+0.55)
Aerie Pharma craters 66% after hours on failed Rhopressa trial
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 3:51PM CDT
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals Reports Initial Rhopressa(TM) Phase 3 Efficacy Results
Business Wire - Thu Apr 23, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the results of its first Phase 3 registration trial (Rocket 1) for Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa(TM) compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma. However, Rhopressa(TM) demonstrated non-inferiority compared to timolol for patients in the study with IOP below 26 millimeters of mercury (mmHg) at all nine measured time points and numerical superiority over timolol at the majority of measured time points. As discussed below, approximately 80% of glaucoma patients have IOP of 26mmHg or less at the time of diagnosis. Management will host a conference call to discuss these results at 5:00 p.m. ET today.
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 12:50p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 12.87 (-22.52)
Aerie Pharma: Finding Value In The Ophthalmic Space
Mark Chapman - at Seeking Alpha - Fri Apr 03, 8:31AM CDT
AERI: 12.87 (-22.52)
Aerie Pharma completes enrollment in Phase 3 Rhopressa study
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:52AM CDT
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial ("Rocket 2" of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Tue Mar 24, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's second Phase 3 registration trial ("Rocket 2" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. The Company's Phase 3 program also includes "Rocket 1," a 90-day efficacy registration trial for which data are expected mid-second quarter 2015, and "Rocket 3," a one-year, safety-only registration trial in Canada. Pending successful results from the Phase 3 registration studies, the Company expects to submit a New Drug Application filing by mid-2016.
AERI: 12.87 (-22.52)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in March
Business Wire - Tue Mar 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in March.
AERI: 12.87 (-22.52)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.17 (+0.02), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ITEK: 5.61 (+0.86), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), FOMX: 10.46 (-0.44), AERI: 12.87 (-22.52), CBMG: 29.51 (-1.85)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:58PM CST
AERI: 12.87 (-22.52)
Nasdaq stocks posting largest volume increases
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.28 (-0.05), SPNC: 26.52 (-8.18), DNBF: 25.62 (+0.62), LPCN: 6.85 (-0.27), GBNK: 15.74 (-1.12), AERI: 12.87 (-22.52), PFBX: 9.33 (+0.12)
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 24, 7:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
MXWL: 6.33 (-0.85), SPNC: 26.52 (-8.18), AMSC: 6.88 (-3.12), HWAY: 17.61 (-1.89), NTGR: 30.00 (-4.17), AERI: 12.87 (-22.52)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims against Aerie Pharmaceuticals, Inc.
Business Wire - Fri Apr 24, 4:05PM CDT
The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) resulting from allegations that Aerie may have issued materially misleading business information to the investing public.
AERI: 12.87 (-22.52)
Investor Alert: Investigation of Aerie Pharmaceuticals, Inc. Announced by Holzer & Holzer, LLC
Business Wire - Fri Apr 24, 12:36PM CDT
Holzer & Holzer, LLC is investigating whether recent statements issued by Aerie Pharmaceuticals, Inc. LTD ("Aerie" or the "Company"
(Nasdaq: AERI) regarding its business and operations complied with federal and state laws. On April 23, 2015, Aerie announced that its experimental drug, Rhopressa, failed to achieve its primary efficacy endpoint during recent Phase 3 registration trials. The price of Aerie stock fell significantly on the news as the company was downgraded by analysts. AERI: 12.87 (-22.52)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:45AM CDT
INNL: 9.90 (+1.28), AWAY: 27.18 (-4.99), ACTG: 11.10 (+1.08), AERI: 12.87 (-22.52), DV: 30.70 (-6.87), CVTI: 33.15 (-2.44), MXWL: 6.33 (-0.85), TBI: 29.20 (+4.39), NFEC: 2.13 (-0.17), SPNC: 26.52 (-8.18), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), CPRX: 3.69 (-0.98), LOOK: 1.97 (+0.37), TRN: 28.70 (-4.66), IMH: 19.20 (+4.78), PGI: 10.79 (+1.29), FPP: 1.69 (+0.46), LEU: 5.22 (+0.58), EHTH: 13.50 (+2.06)
Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc.
PR Newswire - Fri Apr 24, 11:00AM CDT
Bernstein Liebhard LLP is investigating whether (i) Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company"
(NASDAQ: AERI) issued materially false and misleading statements to investors in violation of the federal securities laws; or (ii) the Board of Directors of Aerie breached their fiduciary duties to shareholders. AERI: 12.87 (-22.52)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 8:17AM CDT
AMZN: 445.10 (+55.11), EMES: 44.65 (-5.95), ANY: 4.08 (-0.19), DDD: 27.23 (-2.92), AERI: 12.87 (-22.52), INFY: 31.81 (-3.15), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), TRIL: 24.21 (+2.05), JNPR: 26.14 (+2.14), AMCN: 4.95 (-0.05), AMSC: 6.88 (-3.12), UEC: 2.31 (-0.09), LOOK: 1.97 (+0.37), CTSO: 7.52 (+0.50), RMD: 65.70 (-7.68), SSYS: 51.28 (-3.29), LPCN: 6.85 (-0.27), HMHC: 24.21 (-0.13), MSFT: 47.87 (+4.53), EHTH: 13.50 (+2.06)
Aerie Pharma plunges aftermarket as Rhopressa study fails
AP - Thu Apr 23, 5:42PM CDT
NEW YORK (AP) — Shares of Aerie Pharmaceuticals lost two-thirds of their value in after-market trading after the company said its experimental eye pressure drug Rhopressa failed in a late-stage clinical trial.
AERI: 12.87 (-22.52)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:39PM CDT
MXIM: 32.78 (-1.96), AMZN: 445.10 (+55.11), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), UBNT: 31.29 (-0.14), AWAY: 27.18 (-4.99), ALGN: 59.18 (+3.17), ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52), RIGL: 4.88 (+0.55)
Aerie Pharma craters 66% after hours on failed Rhopressa trial
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 3:51PM CDT
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals Reports Initial Rhopressa(TM) Phase 3 Efficacy Results
Business Wire - Thu Apr 23, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the results of its first Phase 3 registration trial (Rocket 1) for Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa(TM) compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma. However, Rhopressa(TM) demonstrated non-inferiority compared to timolol for patients in the study with IOP below 26 millimeters of mercury (mmHg) at all nine measured time points and numerical superiority over timolol at the majority of measured time points. As discussed below, approximately 80% of glaucoma patients have IOP of 26mmHg or less at the time of diagnosis. Management will host a conference call to discuss these results at 5:00 p.m. ET today.
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 12:50p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 12.87 (-22.52)
Aerie Pharma: Finding Value In The Ophthalmic Space
Mark Chapman - at Seeking Alpha - Fri Apr 03, 8:31AM CDT
AERI: 12.87 (-22.52)
Aerie Pharma completes enrollment in Phase 3 Rhopressa study
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:52AM CDT
AERI: 12.87 (-22.52)
Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial ("Rocket 2"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma Business Wire - Tue Mar 24, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's second Phase 3 registration trial ("Rocket 2"
of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. The Company's Phase 3 program also includes "Rocket 1," a 90-day efficacy registration trial for which data are expected mid-second quarter 2015, and "Rocket 3," a one-year, safety-only registration trial in Canada. Pending successful results from the Phase 3 registration studies, the Company expects to submit a New Drug Application filing by mid-2016. AERI: 12.87 (-22.52)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in March
Business Wire - Tue Mar 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in March.
AERI: 12.87 (-22.52)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.17 (+0.02), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ITEK: 5.61 (+0.86), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), FOMX: 10.46 (-0.44), AERI: 12.87 (-22.52), CBMG: 29.51 (-1.85)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:58PM CST
AERI: 12.87 (-22.52)
